British health regulator National Institute for Health and Clinical Excellence (NICE) has issued a final draft rejecting the prescription of breast cancer drug eribulin by the NHS for treating patients who have advanced breast cancer.
The draft revealed that while the drug could extend patients' lives by 2.7 months on average, it came with a number of side effects, such as anemia, fatigue and hair loss, which other treatments did not have.
Advertisement"Although the evidence presented to the independent advisory committee indicated that eribulin may help some patients live for a little longer, it also caused more undesirable side effects than other treatments already available, and the effects on health-related quality of life had not been adequately assessed", chief executive of NICE, Sir Andrew Dillon said.
P Loss of Productivity is Higher When Employees Report to Work During Illness Elderly Population in the US Hits a Peak M
You May Also Like